SCOL fundamentals

Scandion Oncology A/S is a clinical-stage biotechnology company, which engages in the development of drugs for the treatment of cancers. Its lead product candidate is SCO-101, an oral compound that enhances the effects of standard anti-cancer treatment when given in combination and to reverse several types of drug resistance of cancer cells. The company was founded by Nils Aage Brünner, Jan Stenvang, and Kim Arvid Nielsen in 2017 and is headquartered in Copenhagen, Denmark.